MTORC2 and Metabolic Reprogramming in GBM: At the Interface of Genetics and Environment

Brain Pathology

Volumn 25, Issue 6, 2015, Pages 755-759

  Masui, Kenta ^a   Cavenee, Webster K ^b   Mischel, Paul S ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

drug resistance; glioblastoma; metabolic reprogramming; mTORC2; nutrient

Indexed keywords

GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL METABOLISM; DRUG RESISTANCE; GENETICS; GLIOBLASTOMA; HUMAN; METABOLIC REPROGRAMMING; NUCLEAR REPROGRAMMING; NUTRIENT AVAILABILITY; ONCOGENE C MYC; BRAIN TUMOR; METABOLISM; PHYSIOLOGY;

BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MULTIPROTEIN COMPLEXES; TOR SERINE-THREONINE KINASES;

EID: 84946210175     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12307     Document Type: Article

References (38)

1. Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, et al (2013) EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab 17: 1000-1008.
2. Bai D, Ueno L, Vogt PK, (2009) Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125: 2863-2870.
3. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al (2013) The somatic genomic landscape of glioblastoma. Cell 155: 462-477.
4. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
5. Cloughesy TF, Cavenee WK, Mischel PS, (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9: 1-25.
6. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18: 153-161.
7. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS, (2008) Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22: 1490-1500.
8. Dang CV, (2013) MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3: a014217.
9. Delpuech O, Griffiths B, East P, Essafi A, Lam EW, Burgering B, et al (2007) Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol 27: 4917-4930.
10. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS, (2015) Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 15: 302-310.
11. Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, et al (2010) FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18: 472-484.
12. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, et al (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2: ra82.
13. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
14. Kaelin WG, McKnight SL, (2013) Influence of metabolism on epigenetics and disease. Cell 153: 56-69.
15. Laplante M, Sabatini DM, (2012) mTOR signaling in growth control and disease. Cell 149: 274-293.
16. Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, et al (2014) Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 20: 306-319.
17. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
18. Lu C, Thompson CB, (2012) Metabolic regulation of epigenetics. Cell Metab 16: 9-17.
19. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159: 1603-1614.
20. Masui K, Cloughesy TF, Mischel PS, (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38: 271-291.
21. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18: 726-739.
22. Masui K, Cavenee WK, Mischel PS, (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25: 364-373.
23. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, et al (2015) Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A 112: 9406-9411.
24. Network CGAR, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
26. Read RD, Cavenee WK, Furnari FB, Thomas JB, (2009) A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 5: e1000374.
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
28. Shimada K, Filipuzzi I, Stahl M, Helliwell SB, Studer C, Hoepfner D, et al (2013) TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks. Mol Cell 51: 829-839.
29. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 1: 524-538.
30. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
31. Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, et al (2015) Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 7: 274ra17.
32. Ward PS, Thompson CB, (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308.
33. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al (2014) mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A 111: 409-414.
34. Weisman R, Cohen A, Gasser SM, (2014) TORC2-a new player in genome stability. EMBO Mol Med 6: 995-1002.
35. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB, (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080.
36. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS, (2014) Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med 11: 255-263.
37. Xiong Y, Guan KL, (2012) Mechanistic insights into the regulation of metabolic enzymes by acetylation. J Cell Biol 198: 155-164.
38. Zinzalla V, Stracka D, Oppliger W, Hall MN, (2011) Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.